NCT01651078

Laser Ablation After Stereotactic Radiosurgery

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 44 (actual)
• Sponsor: Monteris Medical · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The need for new technologies and devices in the field of neurosurgery is well established. In April 2013, FDA cleared NeuroBlate™ System, minimally invasive robotic laser thermotherapy tool. It employs a pulsed surgical laser to deliver targeted energy to abnormal brain tissue caused by tumors and lesions. This post-marketing, multi-center study will include patients with metastatic tumors who failed stereotactic radiosurgery and are already scheduled for NeuroBlate procedure. The study will collect clinical outcome, Quality of Life (QoL) and, where feasible, healthcare utilization data for publication.

Conditions

• Metastatic Brain Tumors
• Progression
• Radiation Necrosis
• Quality of Life

Timeline

• Start date: 2012-07-01
• Primary completion: 2016-08-01
• Completion: 2016-08-01
• First posted: 2012-07-26
• Last updated: 2024-04-15
• Results posted: 2019-08-09

Locations

7 sites across 1 country: United States